CDK9 and glioblastoma: Since HK2 and PKM2 promote tumor growth and GSC self-renewal [54,55] and glioblastomas are heavily reliant on glycolysis for energy production [57], targeting CDK9 provides a novel mechanism to exploit these metabolic vulnerabilities.